NCT05225155

Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 104 (actual)
• Sponsor: Faculdade de Medicina do ABC · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

Retrospective study designed to evaluate outcomes in patients undergoing assisted reproduction. Some of them had thrombophilia, and part of them was treated with enoxaparin, started on the day of embryo transfer, and the other part not. Women without thrombophilia formed the control group.

Detailed description

A retrospective study was performed to evaluate the results in 104 patients undergoing to assisted reproduction. Women without thrombophilia were included as controls (n=20), while women with thrombophilia were either treated with 40 mg daily of enoxaparin (treated group, n=54), initiated on the day of embryo transfer, and continued to the week 36 of gestation, or did not receive this medication (untreated group, n= 30).

Conditions

• Infertility, Female
• Thrombophilia
• Fertilization in Vitro

Interventions

Type	Name	Description
DRUG	Enoxaparin	Women with thrombophilia were treated with 40 mg daily of enoxaparin (treated group), initiated on the day of embryo transfer, up to week 36 of gestation

Timeline

• Start date: 2015-02-02
• Primary completion: 2015-11-30
• Completion: 2019-08-31
• First posted: 2022-02-04
• Last updated: 2022-09-10

Locations

1 site across 1 country: Brazil

Regulatory

• FDA-regulated drug study